Becton, Dickinson and Company $BDX Shares Bought by D.A. Davidson & CO.

D.A. Davidson & CO. grew its holdings in Becton, Dickinson and Company (NYSE:BDX) by 14.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 60,557 shares of the medical instruments supplier’s stock after acquiring an additional 7,503 shares during the period. D.A. Davidson & CO.’s holdings in Becton, Dickinson and Company were worth $11,335,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Brighton Jones LLC boosted its position in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares during the period. RiverGlades Family Offices LLC purchased a new stake in Becton, Dickinson and Company in the second quarter valued at approximately $344,000. Covea Finance boosted its holdings in shares of Becton, Dickinson and Company by 10.7% in the third quarter. Covea Finance now owns 78,847 shares of the medical instruments supplier’s stock valued at $14,758,000 after acquiring an additional 7,610 shares during the period. B. Riley Wealth Advisors Inc. purchased a new position in shares of Becton, Dickinson and Company during the second quarter worth approximately $983,000. Finally, Fort Washington Investment Advisors Inc. OH increased its holdings in shares of Becton, Dickinson and Company by 2.0% in the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 905,757 shares of the medical instruments supplier’s stock valued at $169,531,000 after acquiring an additional 17,844 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $198.91 on Tuesday. The company has a current ratio of 1.11, a quick ratio of 0.64 and a debt-to-equity ratio of 0.69. The stock has a 50 day simple moving average of $191.27 and a 200-day simple moving average of $187.41. The company has a market cap of $56.67 billion, a price-to-earnings ratio of 34.12, a price-to-earnings-growth ratio of 1.80 and a beta of 0.23. Becton, Dickinson and Company has a 12-month low of $162.29 and a 12-month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The firm had revenue of $5.32 billion for the quarter. On average, equities analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Monday, December 8th were paid a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.1%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date was Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 72.04%.

Wall Street Analyst Weigh In

BDX has been the topic of several research reports. Piper Sandler lowered their price objective on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research report on Friday, November 7th. Wall Street Zen downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Bank of America boosted their price target on Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research report on Monday. Argus increased their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $207.18.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 629 shares of the company’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $196.03, for a total transaction of $123,302.87. Following the transaction, the executive vice president directly owned 13,105 shares in the company, valued at approximately $2,568,973.15. This represents a 4.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Bertram L. Scott sold 217 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the sale, the director owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 1,052 shares of company stock worth $201,235. 0.40% of the stock is owned by insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.